12:00 AM
 | 
Nov 08, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Relenza zanamivir inhaled neuraminidase inhibitor regulatory update

BTA partner Glaxo Wellcome plc (London, U.K.) submitted an application for European marketing approval of...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >